Study: Doctors overprescribe ADHD meds to preschoolers, defying expert guidelines

By avagrace // 2025-09-08

Copy

A new study reveals a widespread practice where doctors frequently prescribe stimulant medication to preschool-aged children with ADHD immediately after diagnosis, bypassing recommended first-line behavioral therapies.
This approach directly contradicts established American Academy of Pediatrics (AAP) guidelines, which advise at least six months of behavioral intervention as the initial treatment for this age group.
The use of stimulants in very young children is associated with more pronounced risks and side effects, including irritability, sleep problems, and suppressed appetite, which often leads to families abandoning treatment altogether.
Researchers suggest this trend is driven by systemic barriers, such as limited access to and high costs of behavioral therapy, leading time-strapped pediatricians to opt for a quick pharmaceutical solution.
The study concludes that this represents a systemic failure to follow evidence-based guidelines, prioritizing convenience over proven, sustainable long-term strategies for vulnerable young patients.

A new study reveals that doctors are frequently prescribing powerful stimulant medications to preschool-aged children diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) almost immediately after diagnosis, bypassing recommended first-line behavioral therapies. Researchers from Stanford Medicine uncovered this practice in a study published Aug. 29 in JAMA Network Open. This directly contradicts treatment guidelines set by the American Academy of Pediatrics (AAP) and raises serious questions about the standard of care for the nation’s youngest patients. The research analyzed the health records of over 9,700 children between the ages of three and five diagnosed with ADHD across eight major U.S. pediatric health systems. It found that a staggering 42 percent were prescribed medication within just one month of their diagnosis. For five-year-olds, the median time from diagnosis to prescription was zero days, indicating prescriptions were often written at the very same appointment where the diagnosis was delivered. This rush to medicate stands in stark opposition to the AAP's clear guidelines, which advise that preschoolers should first undergo at least six months of evidence-based behavioral intervention before medication is even considered. (Related: No meds required: 3 ways schools can help ADHD kids without resorting to risky psychiatric drugs.) ADHD is a neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity and impulsivity that interferes with functioning or development. For young children, this often manifests as an inability to sit still, difficulty following instructions, excessive talking and trouble engaging in quiet activities. The AAP's recommended first course of action is not medication, but an approach known as parent training in behavior management. This therapy equips parents with strategies to build positive relationships with their children, use reward systems to reinforce good behavior, and establish consistent routines, effectively teaching the child critical coping and organizational skills. "ADHD in preschool kids is a condition that typically begins to manifest in these early school years," explained Brighteon.AI's Enoch. "It is a commonly diagnosed behavior disorder where children have long-standing difficulty controlling their behaviors and/or paying attention. While more often seen in boys, it is estimated to affect a significant number of children in this age group."

The risks of a pharmaceutical-first approach

While medications like methylphenidate (commonly known by brand names such as Ritalin) are approved for and can be effective in older children, their use in preschoolers is fraught with complications. Young children metabolize these stimulants differently, often experiencing more pronounced side effects such as irritability, aggressiveness, sleep disturbances and suppressed appetite. Dr. Yair Bannett, the study's lead author, noted that this hasty introduction of drugs often leads to "treatment failure," where families alarmed by the side effects abandon treatment altogether, leaving the child's condition unaddressed. This denies the child the potential benefits of a more measured, comprehensive treatment plan. This new data is not an isolated incident, but rather the latest chapter in a decades-long debate surrounding ADHD diagnosis and treatment. Since the 1990s, diagnoses of ADHD in children have soared, coinciding with the rapid expansion of pharmaceutical marketing directly to consumers and physicians. Critics have long argued that normal, high-energy childhood behavior is increasingly being pathologized, creating a lucrative market for drug manufacturers. The study's findings suggest that this culture of quick pharmaceutical fixes has now trickled down to toddlers, despite expert consensus urging caution. The study authors acknowledge that the systemic rush to prescribe is likely driven by significant practical barriers. Access to qualified child behavioral therapists is severely limited in many parts of the country, and even when available, the cost of such therapy can be prohibitive if not covered by insurance. Time-strapped pediatricians, faced with a distressed family and few immediate resources, may see a prescription pad as the only tangible solution they can offer. However, researchers stress that alternatives exist, including guided self-help for parents using online resources and workbooks that teach behavioral management techniques, which pediatricians can and should recommend. Visit PrescriptionWarning.com for more similar stories. Watch this video as Dr. Eric Berg explains that ADHD is not genetic. This video is from the Polyxena Lobkovice channel on Brighteon.com.

NATURAL NEWS

The risks of a pharmaceutical-first approach

More related stories: